128 related articles for article (PubMed ID: 27966655)
1. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
[TBL] [Abstract][Full Text] [Related]
2. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
3. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
[TBL] [Abstract][Full Text] [Related]
4. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
6. A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy.
Somers J; Wilson LA; Kilday JP; Horvilleur E; Cannell IG; Pöyry TA; Cobbold LC; Kondrashov A; Knight JR; Puget S; Grill J; Grundy RG; Bushell M; Willis AE
Genes Dev; 2015 Sep; 29(18):1891-6. PubMed ID: 26338418
[TBL] [Abstract][Full Text] [Related]
7. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
8. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
[TBL] [Abstract][Full Text] [Related]
9. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
10. Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study.
Abdalkhalek ES; Wakeel LME; Nagy AA; Sabri NA
Med Oncol; 2022 Jul; 39(10):152. PubMed ID: 35852645
[TBL] [Abstract][Full Text] [Related]
11. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.
Liu D; Wu J; Shi GY; Zhou HF; Yu Y
Genet Mol Res; 2014 Apr; 13(2):3100-7. PubMed ID: 24782167
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
14. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
16. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Zou HZ; Zhao YQ
Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
[TBL] [Abstract][Full Text] [Related]
17. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.
Mathiaux J; Le Morvan V; Pulido M; Jougon J; Bégueret H; Robert J
Mol Diagn Ther; 2011 Jun; 15(3):159-66. PubMed ID: 21766907
[TBL] [Abstract][Full Text] [Related]
18. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
19. ERCC5 is a novel biomarker of ovarian cancer prognosis.
Walsh CS; Ogawa S; Karahashi H; Scoles DR; Pavelka JC; Tran H; Miller CW; Kawamata N; Ginther C; Dering J; Sanada M; Nannya Y; Slamon DJ; Koeffler HP; Karlan BY
J Clin Oncol; 2008 Jun; 26(18):2952-8. PubMed ID: 18565881
[TBL] [Abstract][Full Text] [Related]
20. Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Aust S; Pils S; Polterauer S; Horvat R; Cacsire Castillo-Tong D; Pils D; Dudek G; Schmid B; Speiser P; Reinthaller A; Grimm C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):518-24. PubMed ID: 23455184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]